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Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder, caused by amyloid material deposition in the upper
dermis. Autosomal dominant PLCA has been mapped earlier to pathogenic missense mutations in the OSMR gene, which encodes
the oncostatin M receptor ß subunit (OSMRß). OSMRß is interleukin-6 family cytokine receptors and possesses two ligands,
oncostatinMandinterleukin-31,whichbothhavebiologicrolesininflammationandkeratinocytecellproliferation,differentiation,
and apoptosis. Here, we identified a new OSMR mutation in a Kurdish family for the first time. Blood samples were taken from
all the affected individuals in the family. DNA extraction was performed using salting out technique. Primers were designed for
intronflankingindividualexonsofOSMRgenewhichweresubjectedtodirectsequencingafterPCRamplificationforeachsample.
Sequencing showed a C/T substitution at position 613 in the proband. This mutation results in an L613S (leucine 613 to serine)
amino acid change. The identified mutation was observed in all affected family members but not in 100 ethnically matched healthy
controls. Elucidating the molecular basis of familial PLCA provides new insight into mechanisms of itch in human skin and may
lead to new therapeutic targets for pruritus.
1. Introduction
Primary localized cutaneous amyloidosis (PLCA MIM
1 0 5 2 5 0 )i so ft e ns e e nb yd e r m a t o l o g i s t sa sac o m m o ni t c h y
skindisease.Thisdisorderusuallypresentswithpruritus,skin
hyperpigmentation,andthickening(lichenification)butwith
no systemic involvement. The histological characteristics of
PLCA include fibrillary degeneration of basal keratinocytes
with increased apoptosis, disruption of dermal unmyeli-
nated nerve fibers, and accumulation of melanosomes in
dermal macrophages and Schwann cells. The amyloid in
PLCA is derived from keratin after epidermal damage and
keratinocyte apoptosis and probably reflects a combination
of degenerated keratin filaments and deposition of serum
amyloid P component and immunoglobulins [1–3]. PLCA
has been reported in association with connective tissue
diseaseslikesystemiclupuserythematosusaswellasmultiple
endocrine neoplasia type 2A [1, 4]. Most PLCA cases are
sporadic but the disorder is more common in certain parts
of the world, including South America and Asia and Middle
East, where up to 10% of cases may be familial with an
autosomal dominant pattern of inheritance [1]. Familial
aggregation and different racial propensity propose that the
genetic factors may have a role in the pathogenesis of PLCA.
OSM is a proinflammatory cytokine that is produced
b ya c t i v a t e dm o n o c y t e sa n dTl y m p h o c y t e sa n ds h a r e s
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 653724, 6 pages
http://dx.doi.org/10.1155/2014/6537242 BioMed Research International
70 y
40 y 25 y
15 y 7 y
Affected = yes
(a) (b)
Figure 1: Primary localized cutaneous amyloidosis. (a) Family pedigree; (b) clinical Image of the leg of the affected daughter.
significant similarities with members of the IL-6 family of
cytokines including IL-6, IL-11, and granulocyte colony-
stimulating factor and many of its biological functions are
alsosharedwithleukemiainhibitoryfactor(LIF)[5–7];these
cytokines are multifunctional protein involved in immunity,
hemopoiesis, bone modeling, and inflammatory processes.
Two types of OSM receptor complexes exist: type I complex
i sc o m p o s e do ft h eg p1 3 0a n dt h eL I Fr e c e p t o rßs u b u n i t s
andtypeIIcomplexiscomposedofgp130receptorchainand
OSMRß chain. Human keratinocytes express a functional
type II OSMR on their surface and OSM is able to directly
trigger keratinocyte activation and differentiation via the
activationoftheSTAT3pathway.TheOSM-inducedsignaling
cascadealsoinvolvesactivationofcertainJanuskinase(JAK1,
J A K 2 ,a n dT y k 2 )a sw e l la sM A P Kp a t h w a y s[ 8–10]. OSMRß
can also be recruited by IL-31. IL-31 receptor A (IL-31RA)
is related to gp130, the common receptor of the IL-6 family
cytokines. Recent studies have shown that IL-31RA forms
a functional receptor complex for IL-31 together with the
be tas u b u n i to fo n c o s ta ti nMr ec e p t o r( O S M R ß ) .I L - 3 1m i gh t
be involved in controlling keratinocyte differentiation and
proliferation and also has a number of effects that point to
a role in the regulation of immune responses in skin [8, 11].
Pathogenic mutation in oncostatin M receptor (OSMR)g e n e
has been identified in PLCA [1–3].
Here, we report the first Kurdish family with PLCA and
investigatetheclinicalfeaturesandgeneticbasisofthedisease
in this family.
2. Materials and Methods
2.1. Patients. After approvalof the study by the Ethical Com-
mittee, a written consent was obtained from all subjects, in
compliancewiththeHelsinkideclaration.Fourbiopsyproven
PLCA patients from a Kurd family in three consecutive gen-
erations(father, two daughters, and one granddaughter) were
enrolled in our study; the patients had chronic pruritus and
skin hyperpigmentation without any systemic involvement.
Thediseasewasmoresevereinthegranddaughterandstarted
earlier (Figure 1). Genomic DNA was extracted from periph-
eral blood samples using salting out technique [12]. Primers
were designed for intron flanking individual exons of OSMR
gene as described previously [1]w h i c hw e r es u b j e c t e dt o
direct sequencing after PCR amplification for each samples.
2.2. Mutation Screening in Normal Healthy Controls Subjects.
In order to rule out the presence of observed mutation
in normal population, an assay was utilized for large scale
mutation detection using PCR-RFLP technique. After PCR
amplificationofmutationflankingregion(primerssequences
a r ea v a i l a b l eu p o nr e q u e s t ) ,t h eP C Rp r o d u c tl e n g t hg e n -
erated was 154bp which after digestion using BclI restric-
tion enzyme yielded 154bps of uncut fragment for the TT
g e n o t y p ea n dt w of r a g m e n t so f1 5 4a n d1 3 2b p sf o rt h eC T
genotype.
Mutation screening was performed on 100 normal indi-
viduals.
2.3. Protein Modeling. The amino acid sequence of the
predicted fibronectin type III domain (FNIII domain) of
h u m a nO S M R ,s p a n n i n gf r o mr e s i d u e4 3 0 – 7 4 0 ,w a ss u b -
mitted to the PSIPRED server (http://bioinf.cs.ucl.ac.uk/psi-
pred/), and a three-dimensional model of the protein was
obtained from the Bioserf module of this server [13]. In
silico mutation induction, further minimization of the native
and mutated structures, and interactions visualization were
done by the use of MOE 2012.10 (Molecular Operating
Environment (MOE), 2012.10; Chemical Computing Group
Inc., 1010 Sherbrooke Street West, Suite no. 910, Montreal,BioMed Research International 3
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Figure 2: Primary localized cutaneous amyloidosis. (a) The chromatogram shows the single nucleotide mutation in patient with Macular
amyloidosis. The C/T substitution in exon 12 of OSMR gene causing L613S (leucine 613 to serine) amino acid transition was observed in all
affected family members and was absent in normal controls. (b) Gel electophoresis [M = marker U = undigested, test control P = proband,
digested C = control, normal individual].
QC, Canada H3A 2R7, 2012). The protein BLAST tool of
the NCBI server (http://blast.ncbi.nlm.nih.gov/)w a su s e dt o
compare the human OSMR with other species protein.
3. Result
Molecular analysis identified a single nucleotide mutation in
the proband, a C/T substitution in exon 12 of OSMR gene.
Thismutationresultsinaleucinetoserineaminoacidchange
at position 613 (L613S). This mutation was present in all
affected family members, whereas none of healthy controls
carried it (Figure 2).
Previously reported mutations of OSMR that have been
r ela tedtoPLCAincl udeK615N[14],G618A,I691T[1],P694L
[15], and G723V [16]. A theoretical model of the three FNIII
domainsofOSMRwasmadeinordertoinvestigatethepossi-
b l ee ff e c to ft h e s em u t a t i o n s .Th efi r s tt w om u t a t i o n s( K 6 1 5 N
a n dG 6 1 8 A )a sw e l la st h eo n et h a tw er e p o r th e r e( L 6 1 3 S )
are all located on the same strand of the second domain of
FNIII (Figure 3). I691, P694, and G723 are positioned in the
first FNIII domain (relative to the transmembrane domain
and based on schematic representation in Arita et al. study
[1] ) .R e s i d u e s6 1 3 ,6 1 5 ,a n d6 1 8a r ec l o s et oe a c ho t h e ra n d
their intramolecular interactions may overlap (Figure 4(a)).
Twohydrogenbonds(hbond)thataredetectedforthesethree
residuesincludeabackbonehbondbetweenL613andtheside
chainofadjacentE614andanhbondbetweenK615andD598
side chains. When observing the residues located in a 4.5 ˚ A
space, around these residues, V531, E534, R600, C611, L612,
E614, and K615 are found to be potentially interacting with
L613, from which R600, E534, and E614 as well as L613 itself
I691
G723
P694
G618
K615
L613
Figure 3: A model of FNIII domains shown with grey cartoons.
Reported mutations of OSMR which are related to PLCA are shown
in spacefill representation.
are again positioned in the vicinity of K615. Similarly, D598,
which has an important interaction with K615, and K616,
whose positioning may impact the orientation of K615, are
both located in the 4.5 ˚ Aa r e aa r o u n dG 6 1 8 .
A mutation of leucine to serine is an important change
from a biochemical point of view; while leucine side chain
h a sm a i n l yt h ep o s s i b i l i t yo fm a k i n gv a nd e rW a a l sc o n t a c t s
with its neighbor residues, serine possesses a hydroxyl group
with the potential of forming hydrogen bonds with the
surrounding solvent or even residues located in the adjacent
strand such as R600, thus shifting the original residue
patternofinteractions(Figure 4(b)).Furthermore,alignment
of the human protein with various species OSMR shows a
conservation of this leucine, which is found, for example,
in Pan troglodytes, Odobenus rosmarus divergens, Felis catus,4 BioMed Research International
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Figure 4: (a) Ball and stick representation of L613, K615, and G618 on the second domain of FNIII. The length of the putative hbonds formed
between L613-E614 and K615-D598 are indicated in (˚ A). (b) Positioning of mutated residues S613, N615, and A618 on the second domain of
FNIII.
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Figure 5: (a) Location of I691 and P694 (ball and stick) on the first domain of FNIII. (b) Positioning of mutated residues T691 and L694. (c)
Location of G723 on the first domain of FNIII. (d) Positioning of mutated residue V723.
Bostaurus,Equuscaballus,Ovisaries,Dasypusnovemcinctus,
and Pteropus alecto. K615 and G618 have also been reported
to be highly conserved residues [1]. The mutation of lysine
(615) to asparagine would directly impact its potential to
form an hbond with the D598 of the adjacent strand. Such
c h a n g e sc o u l dp o t e n t i a l l yl e a dt oc o n f o r m a t i o n a lc h a n g e si n
this domain of FNIII. Finally, the mutation of glycine (618)
to alanine would result in the formation of a side chain
(although not so voluminous), which may have the potential
of making further van der Waals interactions (Figure 4(b)).
Of the three residues reported to mutate that are located
in the first FNIII domain, I691 and P694 are close to
each other and P694 is positioned in a turn (Figure 5(a)).
Isoleucine is an aliphatic residue which may be involvedBioMed Research International 5
in hydrophobic interactions and will be changed to a polar
residue upon mutation to threonine. This threonine would
then have the potential to make new hbonds, for example,
with the adjacent E (696) (Figure 5(b)). Proline is a rigid
residue (Figure 5(a)), and a change to leucine would increase
theflexibilityoftheproteinstructureinthislocation(possibly
affectingtheturnconformation)aswellasprovideapotential
to make van der Waals interactions. Glycine is devoid of side
chain, and the mutation of G723 (Figure 5(c))t oav a l i n e
residue would result in a protrusion from the strand where
i ti sp o s i t i o n e d ,t o w a r dt h ep a r a l l e ls t r a n d ,a n dt h e r ew o u l d
be a potential for interaction with the neighbor P (625)
(Figure 5(d)).
4. Discussion
Although the exact pathogenesis of PLCA remains unclear,
previous observations suggest a link between the IL-31 and
OSM signaling and pathogenesis of PLCA. Overall, the three
mutations that occur on residues 613, 615, and 618 of OSMR𝗽
may all cause some conformational changes in the second
domain of FNIII, but their positioning (more or less on the
same side of a single strand) is suggestive of their putative
directeffectindisruptingintramolecularinteractionsthatare
essential in the dimer formation of OSMR. This is in line
with the previously proposed theory of Arita et al. in [1]a n d
it may be hypothesized that mutations occurring in other
residues located in this strand may also result in deleterious
effects. I691T and P694L mutations that are less exposed on
the protein surface may affect the conformation of the first
FNIII domain, in an intramolecular level, but it should also
be mentioned that, based on our model, these are located in
a part of the protein which has not a very defined secondary
structure composition. The G723V may have similar effects
too. In the case of these three mutations, and specially about
G 7 2 3 V ,b a s e do nt h ep o s i t i o n i n go ft h e s er e s i d u e si no u r
model, the effects may be assumed to be exerted by affecting
the conformation of the protein itself, and have an indirect
effect on the ability of the protein to form heterodimers. This
is a theory that has to be confirmed by further experimental
evidences.
Mutations involving members of the IL-6 receptor gene
family like OSMRß and IL-31RA results in dysfunctionof the
downstreamsignalslikeJak/STAT,Erk1/2,andPI3K/Aktwith
antiapoptoticeffectsinseveraltumorcelllinesandthismight
also be the reason of keratinocyte apoptosis in PLCA [16, 17].
In addition, skin biopsies of patients with PLCA showed
diminished innervations of epidermis and dermoepidermal
junction indicating the involvement of neural system in
this disease [18]. Both OSMRß and IL-31 RA mRNA are
expressed in a subset of small-sized nociceptive neurons of
adult dorsal root ganglia and dermis of the skin [19]. OSM
plays an essential role in the development of a subtype of
nociceptive neurons in the Dorsal root ganglia [18]a n dI L - 3 1
canstimulateunmyelinatedCfibersinthedermis.Decreased
function of OSMRß may lead to degeneration of small nerve
fibers. Severe pruritus observed in lichen amyloidosis might
be the result of the hypersensitivity of the remaining nerve
fibres as a response to an unexplained neurodegeneration of
the absent nerve fibres [16, 20].
Alzheimer’sdisease is a neurodegenerativedisorder asso-
c i a t e dw i t ha m y l o i dd e p o s i t i o nl i k eP L C A .I nt h e s ep a t i e n t s ,
LIF expression was identified in hippocampus and in the
temporalcortex,indicatingaroleforLIFinneuronaldamage
or repair in these sites [21]. LIF and OSM have significant
functional similarities and share type I complex receptor.
W ec a nh y p o t h e s i z et h a t ,i nP L C A ,af u n c t i o n a ld e c r e a s e
in OSMRß and IL-31 RA signaling pathway may cause an
increase in signaling through type I OSM complex (LIF
receptorandgp130),whichmayleadtoaperipheralneurode-
generativeconditionlikeAlzheimer’sdisease.Thishypothesis
needs to be further investigated.
IL-31 has been shown to be one of the many mediators
inducinginflammationandpruritusin atopicdermatitis[22]
a n di t ss e r u ml e v e lc o u l db eu s e da sa no b j e c t i v er e l i a b l e
marker of atopic dermatitis severity in children [23]. L613S
in OSMRß causes reduced IL-31 signaling in PLCA with
severe pruritus which is contrary to the above findings in
atopic dermatitis. This supports that neural components
might have a prominent role in the pathogenesis of PLCA
[16].
It has been shown that IL-31 can induce the secretion of
monocyte chemotactic protein-1 (MCP-1). MCP-1 can attract
monocytes, which would differentiate to macrophages at the
s i t e so fi n j u r yo ri n fl a m m a t i o n .I tc a nb es p e c u l a t e dt h a t
the amyloid clearance of keratinocytes is compromised in
P L C Ab e c a u s eo fl i m i t e dr e c r u i t m e n to fi m m u n ec e l l st o
the lesional sites. Deficiency of this scavenger function has
been also observed in Alzheimer’s disease, which is also
characterizedbyamyloiddeposition.Failureofcellulardebris
clearance from the lesional tissues by the innate immunity
may be a common event in these disorders [24]. Recently,
diminished level of MCP-1 was identified in PLCA skin
[24].
AlthoughPLCAisnotlife-threatening,thediseaseaffects
the patients’ quality of life significantly from severe itch to
undesirable appearance; therefore, new and efficient ther-
apeutic approaches are important. Additional studies are
required to investigate our current hypothesis that can lead
to better treatment and management strategies.
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